Alvotech
Alvotech (ALVO) Revenue
Annual & quarterly revenue history · segment & region breakdown
ALVO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAlvotech trailing twelve-month (TTM) revenue is $0.56B, an increase of 19.74% year-over-year from $0.59B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.59B | +$0.10B | +19.74% |
| 2024-12-31 | $0.49B | +$0.40B | +435.56% |
| 2023-12-31 | $0.09B | +$0.01B | +10.12% |
| 2022-12-31 | $0.08B | +$0.05B | +125.79% |
| 2021-12-31 | $0.04B | -$0.03B | -44.80% |
| 2020-12-31 | $0.07B | +$0.03B | +108.71% |
| 2019-12-31 | $0.03B | — | — |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare ALVO revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Alvotech receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Alvotech reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Alvotech's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ALVO revenue · 4 questionsALVO's trailing twelve-month (TTM) revenue is $0.56B. That is an increase of 19.74% year-over-year from $0.59B in FY2025.
▸ Source: FMP · Alvotech SEC filings · GAAP · Alvotech SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026